Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
1 minute read

Lexicon’s LX9211 Shows Significant And Consistent Benefits In The Treatment Of Painful Diabetic Neuropathy In Full Results From The Phase 2 RELIEF-DPN-1 Trial Presented At The 16th Annual Pain Therapeutics Summit

By Benzinga Newsdesk
November 14, 5:44 PM
  Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6 Significant benefits demonstrated on burning pain and on pain interference with sleep No evidence of withdrawal symptoms or

LXRX

Read More
1 minute read

Eagle Pharmaceuticals Announces FDA Acceptance Of Investigational New Drug Application For CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent For The Adjunct Treatment Of Severe Community-Acquired Bacterial Pneumonia

By Benzinga Newsdesk
November 14, 7:51 AM
-- Expect to begin a Phase 2 study in approximately 276 patients with severe community-acquired pneumonia at approximately 120 sites worldwide -- -- Patient enrollment expected to commence as early as the beginning of

EGRX

Read More
1 minute read

Candel Therapeutics Announces Late-breaking Oral Presentation At SITC Annual Meeting With Data On CAN-2409 In Combination With Nivolumab In A Phase 1 Mechanistic Clinical Trial In Patients With High-grade Glioma

By Benzinga Newsdesk
November 11, 1:00 PM
Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of care Systemic immune activation was observed in peripheral

CADL